Bioventix (BVXP) - Total Liabilities
Based on the latest financial reports, Bioventix (BVXP) has total liabilities worth GBX1.99 Million GBX (≈ $242.48 USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how much of Bioventix's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Bioventix - Total Liabilities Trend (2006–2025)
This chart illustrates how Bioventix's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Bioventix (BVXP) total assets.
Bioventix Competitors by Total Liabilities
The table below lists competitors of Bioventix ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Avation PLC
LSE:AVAP
|
UK | GBX762.44 Million |
|
Duros S.A.
AT:DUR
|
Greece | €9.43 Million |
|
TH1NG AB
ST:TH1NG
|
Sweden | Skr30.89 Million |
|
Pathfinder Ventures Inc
V:RV
|
Canada | CA$13.14 Million |
|
GACM Technologies Limited
NSE:GATECHDVR
|
India | Rs166.67 Million |
|
SEALAND CAP. GA. LS-0001
F:7KM
|
Germany | €4.25 Million |
|
FKS Food Sejahtera Tbk PT
JK:AISA
|
Indonesia | Rp942.71 Billion |
|
Global Energy Metals Corp
V:GEMC
|
Canada | CA$619.86K |
Liability Composition Analysis (2006–2025)
This chart breaks down Bioventix's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Bioventix balance sheet independence to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.12 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bioventix's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bioventix (2006–2025)
The table below shows the annual total liabilities of Bioventix from 2006 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | GBX1.31 Million ≈ $159.64 |
-24.08% |
| 2024-06-30 | GBX1.73 Million ≈ $210.28 |
+41.90% |
| 2023-06-30 | GBX1.22 Million ≈ $148.19 |
-6.06% |
| 2022-06-30 | GBX1.30 Million ≈ $157.74 |
+19.28% |
| 2021-06-30 | GBX1.09 Million ≈ $132.24 |
+39.54% |
| 2020-06-30 | GBX778.87K ≈ $94.77 |
-1.09% |
| 2019-06-30 | GBX787.43K ≈ $95.81 |
-8.93% |
| 2018-06-30 | GBX864.66K ≈ $105.20 |
+266.29% |
| 2017-06-30 | GBX236.06K ≈ $28.72 |
-58.43% |
| 2016-06-30 | GBX567.86K ≈ $69.09 |
+78.66% |
| 2015-06-30 | GBX317.84K ≈ $38.67 |
-40.13% |
| 2014-06-30 | GBX530.91K ≈ $64.60 |
+72.75% |
| 2013-06-30 | GBX307.34K ≈ $37.39 |
+43.92% |
| 2012-06-30 | GBX213.54K ≈ $25.98 |
+12.03% |
| 2011-06-30 | GBX190.62K ≈ $23.19 |
+5.32% |
| 2010-06-30 | GBX181.00K ≈ $22.02 |
-88.15% |
| 2009-06-30 | GBX1.53 Million ≈ $185.91 |
+27.97% |
| 2008-06-30 | GBX1.19 Million ≈ $145.28 |
+7.86% |
| 2007-06-30 | GBX1.11 Million ≈ $134.69 |
+0.82% |
| 2006-06-30 | GBX1.10 Million ≈ $133.59 |
-- |
About Bioventix
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. It offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; Pyrene 1-hydroxypyrene glucuronide (HOP-G) ELISA kit to monitor human exposure to industrial pollutants; and Pyrene (HOP-G) lateral flo… Read more